ATC Group: J05AB09 Famciclovir

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J05AB09 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J05 Antivirals for systemic use
3 J05A Direct acting antivirals
4 J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors
5 J05AB09 Famciclovir

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 750 mg

Active ingredients in J05AB09

Active Ingredient Description
Famciclovir

Famciclovir is the oral prodrug of penciclovir. Famciclovir is rapidly converted in vivo into penciclovir, which has in vitro activity against herpes simplex viruses (HSV types 1 and 2), varicella zoster virus (VZV), Epstein-Barr virus and cytomegalovirus.

Related product monographs

Title Information Source Document Type  
FAMVIR Film-coated tablets Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

Australia (AU)

Austria (AT)

Brazil (BR)

Canada (CA)

Cyprus (CY)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Japan (JP)

Malta (MT)

New Zealand (NZ)

South Africa (ZA)

Spain (ES)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.